The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Cited by
Sorted by citations
Items 501–600 of 1,010
Hypopharyngeal carcinoma: Do you know your guidelines?
Kwon, D. I., & Miles, B. A. (2018) · Head & Neck · doi:10.1002/hed.24752 · Cited by 89
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Turgeon, G., Weickhardt, A. J., Azad, A., Solomon, B., & Siva, S. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12046 · Cited by 89
Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 90
Ando, Y., Hayashi, T., Sugimoto, R., Nishibe, S., Ito, K., Kawada, K., Ikeda, Y., Yamada, S., & Imaizumi, K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00881-6 · Cited by 88
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
Witzleben, A. V., Wang, C., Laban, S. A., Savelyeva, N., & Ottensmeier, C. H. H. (2020) · Cells · doi:10.3390/cells9092103 · Cited by 93
NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma
Shah, P. A., Huang, C., Li, Q., Kazi, S. A., Byers, L. A., Wang, J., Johnson, F. M., & Frederick, M. J. (2020) · Cells · doi:10.3390/cells9122677 · Cited by 92
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Andrews, L. P., Somasundaram, A., Moskovitz, J. M., Szymczak-Workman, A. L., Liu, C., Cillo, A. R., Huang, L., Normolle, D. P., Moynihan, K. D., Taniuchi, I., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc2728 · Cited by 87
Self-citationNew Insights Into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis
Chen, S., Hsiao, S., Chang, K., & Chang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052252 · Cited by 93
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M., & Neskey, D. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.007 · Cited by 93
Laubli, H. P., Koelzer, V. H., Matter, M. S., Herzig, P., Schlienger, B. D., Wiese, M. N., Lardinois, D., Mertz, K. D., & Zippelius, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386362 · Cited by 88
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2017) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 88
Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 88
Zhao, X., Shen, J., Ivaturi, V. D., Gopalakrishnan, M., Feng, Y., Schmidt, B. J., Statkevich, P., Goodman, V. L., Gobburu, J. V. S., Bello, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.015 · Cited by 88
Chung, C., Lin, C., Chen, C., Hsueh, C., Chang, Y., Wang, C., Chu, P., Tai, S., & Yang, M. (2023) · Advanced Science · doi:10.1002/advs.202204514 · Cited by 90
Maruse, Y., Kawano, S., Jinno, T., Matsubara, R., Goto, Y., Kaneko, N., Sakamoto, T., Hashiguchi, Y., Moriyama, M., Toyoshima, T., et al. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.01.004 · Cited by 86
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 86
Segal, N. H., Ou, S. I., Balmanoukian, A. S., Fury, M. G., Massarelli, E., Brahmer, J. R., Weiss, J., Schöffski, P., Antonia, S. J., Massard, C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.029 · Cited by 86
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 85
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma
Razzo, B. M., Ludwig, N., Hong, C., Sharma, P., Fabian, K. P., Fecek, R. J., Storkus, W. J., & Whiteside, T. L. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz124 · Cited by 89
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 93
Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S. C. H., Saunders, M. P., Gilbert, D. C., Jensen, L. H., Samalin, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100529 · Cited by 86
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 101
Mo, J., Hu, X., Gu, L., Chen, B., Khadaroo, P. A., Shen, Z., Dong, L., Lv, Y., Chitumba, M. N., & Liu, J. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-1792-4 · Cited by 86
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Liang Cheng, C., Antonio Lopez-beltran, B., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 85
William, W. N., Zhao, X., Bianchi, J. J., Lin, H. Y., Cheng, P., Lee, J. J., Carter, H. K., Alexandrov, L. B., Abraham, J. P., Spetzler, D. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022655118 · Cited by 84
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Wang, R., Li, C., Cheng, Z., Li, M., Shi, J., Zhang, Z., Jin, S., & Ma, H. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114686 · Cited by 88
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients
Wyss, J., Dislich, B., Koelzer, V. H., Galván, J. A., Dawson, H., Hädrich, M., Inderbitzin, D., Lugli, A., Zlobec, I., & Berger, M. D. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.007 · Cited by 82
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Haratani, K., Yonesaka, K., Takamura, S., Maenishi, O., Kato, R., Takegawa, N., Kawakami, H., Tanaka, K., Hayashi, H., Takeda, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126598 · Cited by 85
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 85
Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer
Feng, C. H., Mell, L. K., Sharabi, A. B., McHale, M. T., & Mayadev, J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.05.003 · Cited by 86
HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?
Augustin, J., Lépine, C., Morini, A., Brunet, A., Veyer, D., Brochard, C., Mirghani, H., Péré, H., & Badoual, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01751 · Cited by 71
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
Fasano, M., Corte, C. M. D., Viscardi, G., Liello, R. D., Paragliola, F., Sparano, F., Iacovino, M. L., Castrichino, A., Doria, F., Sica, A., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920949418 · Cited by 84
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Naidoo, J., Cappelli, L. C., Forde, P. M., Marrone, K. A., Lipson, E. J., Hammers, H. J., Sharfman, W. H., Le, D. T., Baer, A. N., Shah, A. A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0390 · Cited by 81
Jahan, N., Talat, H., & Curry, W. T. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox125 · Cited by 83
Krishna, S., Ulrich, P. R., Wilson, E., Parikh, F., Narang, P., Yang, S., Read, A. K., Kim‐Schulze, S., Park, J. G., Posner, M. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0163 · Cited by 85
Lechien, J., Descamps, G., Seminerio, I., Furgiuele, S., Dequanter, D., Mouawad, F., Badoual, C., Journé, F., & Saussez, S. (2020) · Cancers · doi:10.3390/cancers12051060 · Cited by 76
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02404-x · Cited by 82
Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
Qian, J. M., & Schoenfeld, J. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.608772 · Cited by 84
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 84
Self-citationMatsuda, T., Leisegang, M., Park, J.-H., Ren, L., Kato, T., Ikeda, Y., Harada, M., Kiyotani, K., Lengyel, E. R., Fleming, G. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0142 · Cited by 83
Yu, Y., & Lee, N. Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0405 · Cited by 91
Correlation between patients' age and cancer immunotherapy efficacy.
Wu, Q., Wang, Q., Tang, X., Xu, R., Zhang, L., Chen, X., Xue, Q., Wang, Z., Shi, R., Wang, F., et al. (2019) · Europe PMC (PubMed Central) · doi:10.1080/2162402x.2019.1568810 · Cited by 84
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 83
Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M., & Day, T. A. (2019) · Head & Neck · doi:10.1002/hed.26036 · Cited by 83
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 84
Hecht, M., Gostian, A., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Hautmann, M., Klautke, G., Laban, S. A., Brunner, T. B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001378 · Cited by 84
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 87
Foster, C. C., Couey, M., Kochanny, S. E., Khattri, A., Acharya, R. K., Tan, Y. C., Brisson, R. J., Leidner, R. S., & Seiwert, T. Y. (2021) · Cancer · doi:10.1002/cncr.33780 · Cited by 83
A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers
Xu, J., Wang, X., Zhu, C., & Wang, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.997633 · Cited by 85
Smith, J. D., Shuman, A. G., & Riba, M. B. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0811-9 · Cited by 81
Targeting cancer stem cells in squamous cell carcinoma
Chen, D., & Wang, C. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz016 · Cited by 83
Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 80
Galvis, M. M., Borges, G. Á., de Oliveira, T. B., de Toledo, I. P., CASTILHO, R. M., Guerra, E. N. S., Kowalski, L. P., & SQUARIZE, C. H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102966 · Cited by 88
Peng, L., Qin, B., Xiao, K., Xu, S., Yang, J., Zang, Y., Stebbing, J., & Xie, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781333 · Cited by 84
Watermann, C., Pasternack, H., Idel, C., Ribbat‐Idel, J., Brägelmann, J., Kuppler, P., Offermann, A., Jonigk, D. D., Kühnel, M., Schröck, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0197 · Cited by 86
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Matsukane, R., Watanabe, H., Minami, H., Hata, K., Suetsugu, K., Tsuji, T., Masuda, S., Okamoto, I., Nakagawa, T., Ito, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79397-6 · Cited by 83
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
Portuguese, A. J., Tykodi, S. S., Blosser, C. D., Gooley, T., Thompson, J. A., & Hall, E. T. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7009 · Cited by 85
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Pang, L., Chen, G., Xu, J. Y., Jia, Y., Chai, J., Huang, R., Li, A., Ge, H., Yu, S., & Cheng, H. (2022) · Cancers · doi:10.3390/cancers14235727 · Cited by 93
Harrington, K. J., Ferris, R. L., Gillison, M. L., Tahara, M., Argiris, A., Fayette, J., Schenker, M., Bratland, Å., Walker, J. W. T., Grell, P., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0147 · Cited by 81
Self-citationEcharti, A., Hecht, M., Büttner-Herold, M., Haderlein, M., Hartmann, A., Fietkau, R., & Distel, L. (2019) · Cancers · doi:10.3390/cancers11091398 · Cited by 87
Severe Esophagitis and Gastritis from Nivolumab Therapy
Boike, J. R., & DeJulio, T. J. (2017) · ACG Case Reports Journal · doi:10.14309/crj.2017.57 · Cited by 80
Bossi, P., Miceli, R., Locati, L. D., Ferrari, D., Vecchio, S., Moretti, G., Denaro, N., Caponigro, F., Airoldi, M., Moro, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx439 · Cited by 80
Self-citationTrommer, M., Yeo, S. Y., ten Persigehl, T., Bunck, A., Grüll, H., Schlaak, M. S., Theurich, S., von Bergwelt‐Baildon, M., Morgenthaler, J., Herter, J. M., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00511 · Cited by 80
Hsieh, C., Wang, H., Wu, M., Chang, K., Chang, P., Liao, C., & Liau, C. (2019) · Head & Neck · doi:10.1002/hed.25932 · Cited by 83
Single-cell sequencing and its applications in head and neck cancer
Qi, Z., Barrett, T. F., Parikh, A. S., Tirosh, I., & Puram, S. V. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104441 · Cited by 82
Ohmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 80
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 82
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 82
Borel, C., Jung, A. C., & Burgy, M. (2020) · Cancers · doi:10.3390/cancers12092691 · Cited by 78
Recurrent respiratory papillomatosis: A 2020 perspective
Benedict, J. J., & Derkay, C. S. (2021) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.545 · Cited by 91
Wang, Z., Goto, Y., Allevato, M. M., Wu, V. H., Saddawi‐Konefka, R., Gilardi, M., Alvarado, D., Yung, B. S., O’Farrell, A., Molinolo, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22619-w · Cited by 81
Macrophages as a “weapon” in anticancer cellular immunotherapy
Aminin, D. L., & Wang, Y. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12405 · Cited by 82
Qiu, M., Zhang, Y., Guo, Y., Guo, W., Nian, W., Liao, W., Xu, Z., Zhang, W., Zhao, H., Wei, X., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0503 · Cited by 80
Newly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 87
Wang, J., Xie, T., Wang, B., William, W. N., Heymach, J. V., El‐Naggar, A. K., Myers, J. N., & Caulı́n, C. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0108 · Cited by 78
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
Jung, K., Kang, H., & Mehra, R. (2018) · Cancers of the Head & Neck · doi:10.1186/s41199-018-0030-z · Cited by 78
Boxberg, M., Leising, L., Steiger, K., Jesinghaus, M., Alkhamas, A., Mielke, M., Pfarr, N., Götz, C., Wolff, K. D., Weichert, W., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800242 · Cited by 79
Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 83
Patil, V., Noronha, V., Joshi, A., Dhumal, S. B., Mahimkar, M. B., Bhattacharjee, A., Gota, V. S., Pandey, M. K., Menon, N. S., Mahajan, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01076 · Cited by 79
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
Szturz, P., & Vermorken, J. B. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104492 · Cited by 79
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02605-9 · Cited by 86
Guidi, A., Codecà, C., & Ferrari, D. (2018) · Medical Oncology · doi:10.1007/s12032-018-1096-5 · Cited by 68
Activated HGF-c-Met Axis in Head and Neck Cancer
Arnold, L., Enders, J. D., & Thomas, S. M. (2017) · Cancers · doi:10.3390/cancers9120169 · Cited by 80
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long, J., Zhang, Q., & Rongxin, Z. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0086 · Cited by 82
Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 80
Haider, S. P., Burtness, B. A., Yarbrough, W. G., & Payabvash, S. (2020) · Cancers of the Head & Neck · doi:10.1186/s41199-020-00053-7 · Cited by 81
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 79
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 76
T-cell repertoire diversity: friend or foe for protective antitumor response?
Porciello, N., Franzese, O., D’Ambrosio, L., Palermo, B., & Nisticò, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02566-0 · Cited by 88
Saba, N. F., Steuer, C. E., Ekpenyong, A., McCook‐Veal, A. A., Magliocca, K. R., Patel, M. R., Schmitt, N. C., Stokes, W. A., Bates, J. E., Rudra, S. F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02275-x · Cited by 83
Self-citationDistinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Li, H., Zandberg, D. P., Kulkarni, A., Chiosea, S. I., Santos, P. M., Isett, B. R., Joy, M., Sica, G., Contrera, K. J., Tatsuoka, C. M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.026 · Cited by 85
Self-citationLanier, C. M., Hughes, R. T., Ahmed, T., LeCompte, M. C., Masters, A. H., Petty, W. J., Ruiz, J., Triozzi, P. L., Su, J., O’Neill, S., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz004 · Cited by 77
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Awadalla, M., Golden, D. L. A., Mahmood, S., Alvi, R. M., Mercaldo, N. D., Hassan, M. Z. O., Banerji, D., Rokicki, A., Mulligan, C. P., Murphy, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0535-y · Cited by 78
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
